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Abstract 
A statement on measuring blood omega-3 long chain polyunsaturated fatty acid levels was developed 
and edited based on input from ISSFAL members and accepted by vote of the ISSFAL Board of Directors. 
Summary of Statement: Omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) levels at baseline 
and post-intervention should be assessed and reported in future research to evaluate the efficacy of n-3 
LCPUFA supplementation: b ecause; 1. there are numerous factors that affect n-3 LCPUFA levels in 
humans as described in the systematic literature review [1]; 2. assessing intake of n-3 LCPUFA from the 
diet and/or supplements is not sufficient to accurately determine n-3 LCPUFA levels in humans; 3. some 
studies do not provide sufficient doses of n-3 LCPUFA to produce a significant impact on bloodstream/
organ content and there is substantial variability in the uptake of n-3 LPCUFA into tissues between 
individuals. In secondary analyses, clinical trials should consider the influence of fatty acid status 
(baseline, endpoint and change from baseline to endpoint) on the outcome variables. 
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A statement on measuring blood omega-3 long chain polyunsaturated fatty acid levels developed 
and edited based on input from ISSFAL members and accepted by vote of the ISSFAL Board of 
Directors. 
Summary of Statement 
Omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) levels at baseline and post-
intervention should be assessed and reported in future research to evaluate the efficacy of n-3 
LCPUFA supplementation 
Because: 
1. There are numerous factors that affect n-3 LCPUFA levels in humans as described in the 
systematic literature review [1]. 
2. Assessing intake of n-3 LCPUFA from the diet and/or supplements is not sufficient to 
accurately determine n-3 LCPUFA levels in humans. 
3. Some studies do not provide sufficient doses of n-3 LCPUFA to produce a significant impact 
on bloodstream/organ content and there is substantial variability in the uptake of n-3 
LPCUFA into tissues between individuals. In secondary analyses, clinical trials should 
consider the influence of fatty acid status (baseline, endpoint and change from baseline to 





It is becoming increasingly clear that n-3 LCPUFA play an important role in human health [2]. N-3 
LCPUFA have been shown to be important for neurological development [3, 4], cardiovascular health 
[5, 6] and there is emerging evidence of their beneficial role in other disease states, including mental 
health conditions [7]. 
Several mechanisms have been suggested for these potential health benefits [8], including effects on 
cell membranes which can influence signal transduction, promotion of neuronal growth, altering 
neurotransmitter release, and facilitating glucose uptake from the endothelial cells into the brain.  
N-3 LCPUFA are also important precursors of the eicosanoids and docosanoids, which have anti-
thrombotic and vasodilatory effects [8]. 
The evidence for the above-mentioned potential health benefits are derived from a large number of 
studies, including both epidemiological/observational studies and baseline data from randomised, 
controlled trials (RCT). However, many of these studies have failed to include measurements of n-3 
LCPUFA levels. This may have serious implications for their ability to draw correct conclusions about 
the effects of omega-3 on the measured outcome/s. 
The recently published systematic literature review [1] highlights that there are many factors 
associated with the n-3 LCPUFA levels of an individual. Therefore, the aims of the current statement 
paper are to: 1. Recommend that researchers should measure n-3 LCPUFA levels at baseline and 
post-intervention, 2. report on the full fatty acid results in future research and 3. analyse the results 
as intention to treat, but also to analyse by the effect of the change of n-3 LCPUFA levels and the 
change in the outcome variable(s) where possible.  
Methods 
Professors Barbara Meyer and Renate de Groot proposed to the ISSFAL executive board to write a 
statement about the importance of measuring n-3 LCPUFA levels in research. After receiving a 
positive reply from the executive board and support from the ISSFAL board, the procedure for 
writing ISSFAL statements, as described on the ISSFAL website 
(http://www.issfal.org/statements/procedures-for-policy-statements), was followed. After a review 
by the ISSFAL Board, it became clear that a systematic review of factors associated with n-3 LCPUFA 
was necessary and has since been published [1]. This statement contains the summarised outcomes 
from the systematic literature review which focused on adults.  
Results of the evaluation 
Terminology 
Various terminologies exist in the literature when describing n-3 LCPUFA levels (defined as n-3 PUFA 
not containing alpha-linolenic acid (ALA, 18:3n-3)) in an individual; including the Holman index; the 
Lands Highly Unsaturated Fatty Acids (HUFA) [9]; long chain omega-3 PUFA [10] and the HS-Omega-3 
Index [11]. The n-3 LCPUFA levels are similar to the afore-mentioned terminologies, and hence n-3 
LCPUFA levels are used in the current statement.   




The n-3 LCPUFA levels in an individual are associated with many factors including diet. It is well-
documented that dietary intake of n-3 LCPUFA is associated with n-3 LCPUFA levels [12, 13]. 
However, dietary intake assessment is less reliable than measuring n-3 LCPUFA levels [14, 15]. The 
non-dietary factors that are associated with n-3 LCPUFA levels are identified in the systematic 
literature review [1] and these are listed in Table 1. The following factors have been found to be 
associated with n-3 LCPUFA levels through assessment of correlation studies and baseline data from 
RCT. 
Results from the systematic literature review [1] showed that in general women had higher levels of 
DHA than men [16, 17]. Studies regarding the genetic factors revealed that mutations in FADS1, 
FADS2 [18-23] and ELOVL2 [22, 23] resulted in lower levels of gamma-linolenic acid (GLA, 18:3n-6), 
arachidonic acid (AA, 20:4n-6), EPA, and DHA due to constraint(s) in the fatty acid metabolism 
pathway, however these constraint(s) may be overcome by supplementation with preformed EPA 
and DHA [24]. N-3 LCPUFA levels are positively associated with increased age [17, 25-47]. There is a 
negative association between participants’ BMI and n-3 LCPUFA levels (erythrocyte EPA and DHA < 
6%) [25, 36, 48-50], but not in individuals with a higher (> 6%) erythrocyte EPA and DHA [34, 46, 51-
53]. Limited data suggests that waist girth [25, 43-45, 49, 50] and also the amount of physical activity 
[46, 51, 52, 54-58] is not associated with n-3 LCPUFA levels. There is a negative association with 
alcohol consumption and n-3 LCPUFA levels, especially when the beverage type is beer or spirit [43- 
45, 59, 60-64]. Lower n-3 LCPUFA levels are found in smokers [25, 39, 43, 44, 51, 65-67]. Regarding 
bioavailability, there is no convincing evidence that krill oil is more bioavailable than fish oil [68, 69]. 
There is no convincing evidence suggesting that the chemical form of n-3 LCPUFA supplements 
matters in terms of bioavailability [70, 71]. With respect to the conversion of plant-derived n-3 fatty 
acids to n-3 LCPUFA there is some evidence that supplementation with ALA increases EPA but not 
DHA and high intakes of linoleic acid reduces the conversion of ALA to EPA 
(http://www.issfal.org/statement-5). Limited evidence suggests that stearidonic acid (SDA, 18:4n-3) 
supplementation increases EPA to a greater extent than supplementation with ALA, but SDA 
supplementation does not increase DHA levels [72]. 
The above findings support the statement that n-3 LCPUFA levels at baseline and post-intervention 
should be assessed and reported in future research to evaluate the effectiveness of n-3 LCPUFA 
supplementation. 
Full fatty acids profiles are encouraged to be reported for the following reasons: (1) invariably 
people are looking at published data from a different perspective and with different goals in mind 
and the full composition is useful in many such ways;  (2) it may also offer some quality control to 
see if the fatty acid profiles are consistent with other reports, especially since such data is often 
reported as a percentage so other fatty acid levels can affect the values in question;  and (3) 
inspection can determine how extensive and complete was the identification of the fatty acids in a 
given tissue.  
In summary, the factors that need to be taken into account when assessing the effect of n-3 LCPUFA 
include sex, age, BMI, alcohol consumption (and type of alcohol) and smoking. 






1. Factors positively associated with the n-3 LCPUFA levels are: age, sex (women less than 50 
years of age).  
2. Factors negatively associated with the n-3 LCPUFA levels are: genetics, BMI (if erythrocyte 
EPA and DHA is less than 6%), smoking and alcohol.  
3. There is inconclusive evidence for the association of waist girth and physical activity with n-3 
LCPUFA levels. 
4. There is no convincing evidence that krill oil versus fish oil, or the chemical form of n-3 
LCPUFA matters in terms of bioavailability. 
5. It is unreliable to predict the n-3 LCPUFA levels in an individual according to food intake 
measured with food frequency questionnaires or comparable instruments.  
Recommendations 
The recommendations below are for people of all ages, however the systematic literature review [1] 
focussed on adults. 
1. It is essential that in all types of research, including cross-sectional, cohort and clinical 
research, the n-3 LCPUFA levels are measured in biological samples, and this should be 
done according to appropriate study protocol. So, for cross-sectional studies the biological 
samples must be measured at one time point and for cohort and clinical intervention 
studies the biological samples must be measured at baseline and follow-up. Whether the 
biological samples should be, whole blood, plasma, or tissue, that is not the focus of this 
statement, however, there are algorithms available for data conversion [16]. Note that there 
are other publications for best practices for research in this field [17, 18]. 
2. In secondary analyses, researchers conducting clinical trials should consider the influence of 
fatty acid status on the outcome variables. 
3. Lastly, publishing full fatty acid profiles (expressed both as percent of total fatty acids and as 






Table 1: Various factors affecting n-3 LCPUFA levels. For further details, please refer to the 
systematic literature review [1]. 
Factors  Direction of association or comments Should take 
factor into 




   
Sex  In general women have higher DHA levels 
than men. 
Yes 
Genetics FADS1 & 
FADS2 
Negative association with GLA, AA, EPA, 
and DHA levels. 
No in 
supplementation 
trials  ELOVL2 Negative association with DHA levels 
Age  n-3 LCPUFA levels are positively 
associated with age 
Yes 
Modifiable factors    
Body size BMI Negative association between n-3 LCPUFA 
levels and BMI in participants with 
erythrocyte EPA and DHA < 6%, but not in 
individuals with erythrocyte EPA and DHA 
>7%. 
Yes 
 Waist girth Inconclusive evidence. No 
Physical activity  Inconclusive evidence. No 
Alcohol  Negative association between alcohol 
consumption and n-3 LCPUFA levels. 
Yes,  
Specification of 
type and amount 
of alcohol is highly 
recommended 
Smoking  Negative association between smoking 
and n-3 LCPUFA levels resulting in 6-17% 
lower n-3 LCPUFA erythrocyte EPA and 




   
Different forms of 
supplements 
 There is no convincing evidence.  No 
Krill oil versus fish 
oil bioavailability 
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